Cardiotoxicity in childhood cancer survivors: Strategies for prevention and management

Danielle Harake, Vivian I. Franco, Jacqueline M. Henkel, Tracie L Miller, Steven E Lipshultz

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Advances in cancer treatment have greatly improved survival rates of children with cancer. However, these same chemotherapeutic or radiologic treatments may result in long-term health consequences. Anthracyclines, chemotherapeutic drugs commonly used to treat children with cancer, are known to be cardiotoxic, but the mechanism by which they induce cardiac damage is still not fully understood. A higher cumulative anthracycline dose and a younger age of diagnosis are only a few of the many risk factors that identify the children at increased risk of developing cardiotoxicity. While cardiotoxicity can develop at anytime, starting from treatment initiation and well into adulthood, identifying the best cardioprotective measures to minimize the long-term damage caused by anthracyclines in children is imperative. Dexrazoxane is the only known agent to date, that is associated with less cardiac dysfunction, without reducing the oncologic efficacy of the anthracycline doxorubicin in children. Given the serious long-term health consequences of cancer treatments on survivors of childhood cancers, it is essential to investigate new approaches to improving the safety of cancer treatments.

Original languageEnglish
Pages (from-to)647-670
Number of pages24
JournalFuture Cardiology
Volume8
Issue number4
DOIs
StatePublished - Jul 1 2012

Fingerprint

Anthracyclines
Neoplasms
Dexrazoxane
Therapeutics
Health
Doxorubicin
Cardiotoxicity
Safety
Pharmaceutical Preparations

Keywords

  • anthracycline
  • cardiotoxicity
  • childhood cancer survivors
  • late effects
  • monitoring
  • prevention
  • risk factors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Molecular Medicine

Cite this

Harake, D., Franco, V. I., Henkel, J. M., Miller, T. L., & Lipshultz, S. E. (2012). Cardiotoxicity in childhood cancer survivors: Strategies for prevention and management. Future Cardiology, 8(4), 647-670. https://doi.org/10.2217/fca.12.44

Cardiotoxicity in childhood cancer survivors : Strategies for prevention and management. / Harake, Danielle; Franco, Vivian I.; Henkel, Jacqueline M.; Miller, Tracie L; Lipshultz, Steven E.

In: Future Cardiology, Vol. 8, No. 4, 01.07.2012, p. 647-670.

Research output: Contribution to journalArticle

Harake, D, Franco, VI, Henkel, JM, Miller, TL & Lipshultz, SE 2012, 'Cardiotoxicity in childhood cancer survivors: Strategies for prevention and management', Future Cardiology, vol. 8, no. 4, pp. 647-670. https://doi.org/10.2217/fca.12.44
Harake, Danielle ; Franco, Vivian I. ; Henkel, Jacqueline M. ; Miller, Tracie L ; Lipshultz, Steven E. / Cardiotoxicity in childhood cancer survivors : Strategies for prevention and management. In: Future Cardiology. 2012 ; Vol. 8, No. 4. pp. 647-670.
@article{d67b55d2115642429141e37b321e7367,
title = "Cardiotoxicity in childhood cancer survivors: Strategies for prevention and management",
abstract = "Advances in cancer treatment have greatly improved survival rates of children with cancer. However, these same chemotherapeutic or radiologic treatments may result in long-term health consequences. Anthracyclines, chemotherapeutic drugs commonly used to treat children with cancer, are known to be cardiotoxic, but the mechanism by which they induce cardiac damage is still not fully understood. A higher cumulative anthracycline dose and a younger age of diagnosis are only a few of the many risk factors that identify the children at increased risk of developing cardiotoxicity. While cardiotoxicity can develop at anytime, starting from treatment initiation and well into adulthood, identifying the best cardioprotective measures to minimize the long-term damage caused by anthracyclines in children is imperative. Dexrazoxane is the only known agent to date, that is associated with less cardiac dysfunction, without reducing the oncologic efficacy of the anthracycline doxorubicin in children. Given the serious long-term health consequences of cancer treatments on survivors of childhood cancers, it is essential to investigate new approaches to improving the safety of cancer treatments.",
keywords = "anthracycline, cardiotoxicity, childhood cancer survivors, late effects, monitoring, prevention, risk factors",
author = "Danielle Harake and Franco, {Vivian I.} and Henkel, {Jacqueline M.} and Miller, {Tracie L} and Lipshultz, {Steven E}",
year = "2012",
month = "7",
day = "1",
doi = "10.2217/fca.12.44",
language = "English",
volume = "8",
pages = "647--670",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Cardiotoxicity in childhood cancer survivors

T2 - Strategies for prevention and management

AU - Harake, Danielle

AU - Franco, Vivian I.

AU - Henkel, Jacqueline M.

AU - Miller, Tracie L

AU - Lipshultz, Steven E

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Advances in cancer treatment have greatly improved survival rates of children with cancer. However, these same chemotherapeutic or radiologic treatments may result in long-term health consequences. Anthracyclines, chemotherapeutic drugs commonly used to treat children with cancer, are known to be cardiotoxic, but the mechanism by which they induce cardiac damage is still not fully understood. A higher cumulative anthracycline dose and a younger age of diagnosis are only a few of the many risk factors that identify the children at increased risk of developing cardiotoxicity. While cardiotoxicity can develop at anytime, starting from treatment initiation and well into adulthood, identifying the best cardioprotective measures to minimize the long-term damage caused by anthracyclines in children is imperative. Dexrazoxane is the only known agent to date, that is associated with less cardiac dysfunction, without reducing the oncologic efficacy of the anthracycline doxorubicin in children. Given the serious long-term health consequences of cancer treatments on survivors of childhood cancers, it is essential to investigate new approaches to improving the safety of cancer treatments.

AB - Advances in cancer treatment have greatly improved survival rates of children with cancer. However, these same chemotherapeutic or radiologic treatments may result in long-term health consequences. Anthracyclines, chemotherapeutic drugs commonly used to treat children with cancer, are known to be cardiotoxic, but the mechanism by which they induce cardiac damage is still not fully understood. A higher cumulative anthracycline dose and a younger age of diagnosis are only a few of the many risk factors that identify the children at increased risk of developing cardiotoxicity. While cardiotoxicity can develop at anytime, starting from treatment initiation and well into adulthood, identifying the best cardioprotective measures to minimize the long-term damage caused by anthracyclines in children is imperative. Dexrazoxane is the only known agent to date, that is associated with less cardiac dysfunction, without reducing the oncologic efficacy of the anthracycline doxorubicin in children. Given the serious long-term health consequences of cancer treatments on survivors of childhood cancers, it is essential to investigate new approaches to improving the safety of cancer treatments.

KW - anthracycline

KW - cardiotoxicity

KW - childhood cancer survivors

KW - late effects

KW - monitoring

KW - prevention

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=84864834120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864834120&partnerID=8YFLogxK

U2 - 10.2217/fca.12.44

DO - 10.2217/fca.12.44

M3 - Article

C2 - 22871201

AN - SCOPUS:84864834120

VL - 8

SP - 647

EP - 670

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 4

ER -